GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jenscare Scientific Co 9877.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

6.49

+0.62%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Jenscare Scientific Co

Its shares trade on HKEX under the ticker 9877.HK. It has been listed since 10 October 2022. In the fiscal year to 31 December 2025, it reported revenue of CN¥102.9m and a net loss of CN¥308.1m. At that date it held total assets of CN¥1.05bn and shareholders' equity of CN¥920.9m.

Jenscare Scientific Co., Ltd. is a holding company, which engages in the development and sale of transcatheter aortic valve systems. The company is headquartered in Ningbo, Zhejiang. The company went IPO on 2022-10-10. The firm develops interventional products for the treatment of structural heart disease. The firm's core products include LuX-Valve and Ken-Valve. LuX-Valve is a transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation and high surgical risk. Ken-Valve is designed for the treatment of severe aortic regurgitation or combined with aortic stenosis. The firm also develops product candidates for the treatment of mitral valve diseases and medical devices for the treatment of heart failure. The firm mainly conducts its businesses in the domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
10 Oct 2022
Employees
337

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Jenscare Scientific develops LuX-Valve for severe tricuspid regurgitation treatment in high-risk patients.
  • Ken-Valve addresses severe aortic regurgitation and combined aortic stenosis with innovative solutions.
  • The company employs 337 full-time staff focused on structural heart disease interventional products.

Weaknesses

  • Jenscare's domestic market focus limits international expansion opportunities.
  • The firm's product portfolio lacks diversity beyond structural heart disease treatments.
  • Limited information on revenue or market share within the domestic market.

Opportunities

  • Expanding into mitral valve disease treatments could leverage existing R&D capabilities.
  • Growing demand for transcatheter valve systems in China's aging population presents opportunities.
  • New product candidates for heart failure devices may attract additional market segments.

Threats

  • Competition from established medical device companies in China's domestic market.
  • Regulatory changes could impact approval processes for new medical devices.
  • Economic downturns might reduce healthcare spending on elective procedures.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.